Sippican Capital Advisors lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,703 shares of the biopharmaceutical company’s stock after purchasing an additional 2,204 shares during the period. Gilead Sciences comprises approximately 1.4% of Sippican Capital Advisors’ investment portfolio, making the stock its 28th largest holding. Sippican Capital Advisors’ holdings in Gilead Sciences were worth $1,483,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Marshall Wace North America L.P. bought a new stake in Gilead Sciences in the 2nd quarter valued at about $51,430,000. Marshall Wace LLP bought a new stake in Gilead Sciences in the 2nd quarter valued at about $11,488,000. Global Thematic Partners LLC raised its stake in Gilead Sciences by 24.0% in the 2nd quarter. Global Thematic Partners LLC now owns 1,046,497 shares of the biopharmaceutical company’s stock valued at $74,069,000 after acquiring an additional 202,758 shares during the period. Wayne Hummer Investments L.L.C. raised its stake in Gilead Sciences by 13.7% in the 2nd quarter. Wayne Hummer Investments L.L.C. now owns 20,286 shares of the biopharmaceutical company’s stock valued at $1,436,000 after acquiring an additional 2,450 shares during the period. Finally, Boston Private Wealth LLC raised its stake in Gilead Sciences by 2.6% in the 2nd quarter. Boston Private Wealth LLC now owns 218,512 shares of the biopharmaceutical company’s stock valued at $15,466,000 after acquiring an additional 5,591 shares during the period. Institutional investors own 75.71% of the company’s stock.
A number of equities research analysts recently issued reports on GILD shares. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets reduced their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, October 27th. Mizuho set a $77.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and lifted their target price for the company from $73.25 to $73.77 in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $87.04.
In related news, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 418,333 shares of company stock valued at $32,742,108 in the last three months. 1.30% of the stock is owned by insiders.
Gilead Sciences, Inc. (GILD) opened at $80.70 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $105,390.00, a PE ratio of 23.19, a PEG ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. research analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s payout ratio is presently 59.77%.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/20/gilead-sciences-inc-gild-stake-raised-by-sippican-capital-advisors.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.